Kronos Worldwide, Inc. produces and markets titanium dioxide pigments (TiO2) in Europe, North America, the Asia Pacific, and internationally. The company produces TiO2 in two crystalline forms, rutile and anatase to impart whiteness, brightness, opacity, and durability for various products, including paints, coatings, plastics, paper, fibers, and ceramics, as well as for various specialty products, such as inks, foods, and cosmetics and pharmaceuticals. It also produces ilmenite, a raw material used directly as a feedstock by sulfate-process TiO2 plants; iron-based chemicals, which are used as treatment and conditioning agents for industrial effluents and municipal wastewater, as well as in the manufacture of iron pigments, cement, and agricultural products; specialty chemicals for use in the formulation of pearlescent pigments, and production of electroceramic capacitors for cell phones and other electronic devices, as well as for use in natural gas pipe, and other specialty applications. In addition, the company provides technical services for its products. It sells its products under the KRONOS brand through agents and distributors to paint, plastics, decorative laminate, and paper manufacturers. The company was founded in 1916 and is headquartered in Dallas, Texas. Kronos Worldwide, Inc. is a subsidiary of Valhi, Inc.

Kronos Worldwide, Inc.

Kross Limited ( ($IN:KROSS) ) has shared an update. Kross Limited has announced that its 35th Annual General Meeting will be held on 16 September 2...

Kross Limited Sets 35th AGM as Fully Virtual Meeting in September

In a report released today, from Bank of America Securities reiterated a Hold rating on Keros Therapeutics, with a price target of $17.00. In addit...

Keros Therapeutics (KROS) Receives a Hold from Bank of America Securities

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oric Pharmaceuticals (ORIC), ClearPoint Neuro (CLPT)...

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), ClearPoint Neuro (CLPT) and Keros Therapeutics (KROS)

In a report released yesterday, Benjamin Burnett from Wells Fargo assigned a Buy rating to Keros Therapeutics, with a price target of $18.00. Burne...

Wells Fargo Issues a Buy Rating on Keros Therapeutics (KROS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Relay Therapeutics (RLAY) and Keros Therapeutics (KROS). Relay Th...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Relay Therapeutics (RLAY) and Keros Therapeutics (KROS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agios Pharma (AGIO), Novavax (NVAX) and Keros Therapeutics (KROS)...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Agios Pharma (AGIO), Novavax (NVAX) and Keros Therapeutics (KROS)

The latest update is out from Kross Limited ( ($IN:KROSS) ). Kross Limited has notified both BSE Limited and the National Stock Exchange of India t...

Kross Limited Publishes Unaudited Q1 FY27 Results in National Dailies

An update from Keros Therapeutics ( ($KROS) ) is now available. On July 17, 2026, Keros Therapeutics announced that Chief Financial Officer Keith R...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KRO	$8.47	0.00%	566.77K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KRO	$8.47	0%	566.77K
3
4
5
6

KRO

Get Kronos Worldwide, Inc. Data in Excel

Get Kronos Worldwide, Inc. Data in Excel